A significant proportion of people with HIV are coinfected with the hepatitis C virus (HCV). Many of these individuals who are chronically infected with HCV will develop complications. Effective treatments are available to cure HCV infection and reduce morbidity and mortality, but most people with HCV do not receive them. The present study aimed to describe a sample of people co-infected with HIV and HCV and explore barriers and facilitators to HCV care in Puerto Rico. Using a mixed-method design, we reviewed n = 113 randomly selected medical records of people with HIV and HCV coinfection. Then, we conducted 12 qualitative interviews with a purposive sample of HCV treatment stakeholders (e.g., physicians and pharmacists). Findings indicate that coinfected individuals have been living with HIV for an average of 16.6 ± 7.7 years, 41.6% received HCV treatment, and the average time since the latest HCV treatment was 3.9 ± 4.5 years. The most common HCV genotype was 1a (26.5%; n = 30), 40.7% of the participants were treated with direct-acting antivirals, and 42 (91%) achieved a sustained virologic response. Interview findings suggest that access to HCV treatment is limited mainly due to costs, lack of insurance coverage, limited number of providers, stigma, and challenges to engagement in HIV care. A significant proportion of participants received treatment for HCV infection, and, of those, most achieved sustained virological response. Expanding coverage and increasing the number of physicians who could prescribe HCV treatment might reduce the gaps in HCV treatment accessibility and use among people coinfected with HIV and facilitate HCV elimination. Culturally appropriate interventions remain needed to address low HCV disease awareness and stigma.
References
[1]
World Health Organization (2023) HIV/AIDS. https://www.unaids.org/en/resources/fact-sheet
[2]
Platt, L., Easterbrook, P., Gower, E., McDonald, B, Sabin, K., McGowan, C., et al. (2016) Prevalence and burden of HCV Co-Infection in People Living with HIV: A Global Systematic Review and Meta-Analysis. Lancet Infectious Diseases, 16, 797-808. https://doi.org/10.1016/s1473-3099(15)00485-5
[3]
Centers for Disease Control and Prevention (2025) Viral Hepatitis among People with HIV. https://www.cdc.gov/hepatitis/hcp/populations-settings/hiv.html
[4]
Centers for Disease Control and Prevention (2024) Fast Facts: HIV in the United States. https://www.cdc.gov/hiv/data-research/facts-stats/index.html
[5]
Walsh, N. and Maher, L. (2012) HIV and Viral Hepatitis C Coinfection in People Who Inject Drugs: Implications of New Direct Acting Antivirals for Hepatitis C Virus Treatment. Current opinion in HIV and AIDS, 7, 339-344. https://doi.org/10.1097/coh.0b013e328354131e
[6]
Hall, E.W., Bradley, H., Barker, L.K., Lewis, K.C., Shealey, J., Valverde, E., et al. (2024) Estimating Hepatitis C Prevalence in the United States, 2017-2020. Hepatology, 81, 625-636. https://doi.org/10.1097/hep.0000000000000927
[7]
Infectious Diseases Society of America (2019) Recommendations for Testing, Managing, and Treating Hepatitis C|HCV Guidance. https://www.hcvguidelines.org/
[8]
Barua, S., Greenwald, R., Grebely, J., Dore, G.J., Swan, T. and Taylor, L.E. (2015) Restrictions for Medicaid Reimbursement of Sofosbuvir for the Treatment of Hepatitis C Virus Infection in the United States. AnnalsofInternalMedicine, 163, 215-223. https://doi.org/10.7326/m15-0406
[9]
Canary, L.A., Klevens, R.M. and Holmberg, S.D. (2015) Limited Access to New Hepatitis C Virus Treatment under State Medicaid Programs. AnnalsofInternalMedicine, 163, 226-228. https://doi.org/10.7326/m15-0320
[10]
Ward, J.W. and Mermin, J.H. (2015) Simple, Effective, but Out of Reach? Public Health Implications of HCV Drugs. NewEnglandJournalofMedicine, 373, 2678-2680. https://doi.org/10.1056/nejme1513245
[11]
Millman, A.J., Ntiri-Reid, B., Irvin, R., Kaufmann, M.H., Aronsohn, A., Duchin, J.S., Scott, J.D. and Vellozzi, C. (2017) Barriers to Treatment Access for Chronic Hepatitis C Virus Infection: A Case Series. Topics in Antiviral Medicine, 25, 110-113.
[12]
Pérez, C.M., Marrero, E., Meléndez, M., Adrovet, S., Colón, H., Ortiz, A.P., et al. (2010) Seroepidemiology of Viral Hepatitis, HIV and Herpes Simplex Type 2 in the Household Population Aged 21-64 Years in Puerto Rico. BMCInfectiousDiseases, 10, Article No. 76. https://doi.org/10.1186/1471-2334-10-76
[13]
Colón-López, V., Alvelo-Fernández, P.M., Centeno-Alvarado, N., Agudelo Salas, I.Y., Rolón Colón, Y., Pabón Martínez, M., et al. (2023) Seroprevalence and Risk Factors Associated with Hepatitis C: A Cross-Sectional Study of Persons Who Inject Drugs in Puerto Rico, 2018. BMCPublicHealth, 23, Article No. 704. https://doi.org/10.1186/s12889-023-15341-3
[14]
Gelpí-Acosta, C., Rodríguez-Díaz, C.E., Aponte-Meléndez, Y. and Abadie, R. (2020) Puerto Rican Syndemics: Opiates, Overdoses, HIV, and the Hepatitis C Virus in a Context of Ongoing Crises. AmericanJournalofPublicHealth, 110, 176-177. https://doi.org/10.2105/ajph.2019.305487
[15]
Hernández, D., Castellón, P.C., Fernández, Y., Torres-Cardona, F.A., Parish, C., Gorshein, D., et al. (2017) When “The Cure” Is the Risk: Understanding How Substance Use Affects HIV and HCV in a Layered Risk Environment in San Juan, Puerto Rico. HealthEducation&Behavior, 44, 748-757. https://doi.org/10.1177/1090198117728547
[16]
Abadie, R. and Dombrowski, K. (2020) “Caballo”: Risk Environments, Drug Sharing and the Emergence of a Hepatitis C Virus Epidemic among People Who Inject Drugs in Puerto Rico. HarmReductionJournal, 17, Article No. 85. https://doi.org/10.1186/s12954-020-00421-z
[17]
Reyes, J.C., Welch-Lazoritz, M., Zayas-Martinez, L., Khan, B., and Dombrowski, K. (2019) Prevalence and Risk Factors associated with Homelessness among Drug Users in Puerto Rico. Puerto Rico Health Sciences Journal, 38, 54-59.
[18]
Abadie, R., Gelpi-Acosta, C., Davila, C., Rivera, A., Welch-Lazoritz, M. and Dombrowski, K. (2018) “It Ruined My Life”: The Effects of the War on Drugs on People Who Inject Drugs (PWID) in Rural Puerto Rico. InternationalJournalofDrugPolicy, 51, 121-127. https://doi.org/10.1016/j.drugpo.2017.06.011
[19]
Welch-Lazoritz, M., Habecker, P., Dombrowski, K., Rivera Villegas, A., Davila, C.A., Rolón Colón, Y., et al. (2017) Differential Access to Syringe Exchange and Other Prevention Activities among People Who Inject Drugs in Rural and Urban Areas of Puerto Rico. InternationalJournalofDrugPolicy, 43, 16-22. https://doi.org/10.1016/j.drugpo.2016.12.011
[20]
Rodríguez-Díaz, C.E., Santiago-Rodríguez, E.I., Jovet-Toledo, G.G., Santana-Bagur, J., Ron-Suarez, Y., Orengo, J.C., et al. (2019) Comorbidities in a Sample of Adults with HIV in Puerto Rico: An Exploratory Study. HIV/AIDS-ResearchandPalliativeCare, 11, 155-164. https://doi.org/10.2147/hiv.s204985
[21]
Pérez, C.M., del Carmen Santos, M., Torres, A., Grana, C. and Albizu-García, C. (2015) Knowledge of Case Workers and Correctional Officers towards HIV and HCV Infections: Opportunity for Public Health Education in the Correctional System. Puerto Rico Health Sciences Journal, 34, 135-141.
[22]
Zignego, A.L., Monti, M. and Gragnani, L. (2018) Sofosbuvir/Velpatasvir for the Treatment of Hepatitis C Virus Infection. Acta Biomed, 89, 321-331.
[23]
Creswell, J.W. and Clark, P.V.L. (2017) Designing and Conducting Mixed Methods Research. SAGE Publications, Inc.
[24]
Graneheim, U.H. and Lundman, B. (2004) Qualitative Content Analysis in Nursing Research: Concepts, Procedures and Measures to Achieve Trustworthiness. NurseEducationToday, 24, 105-112. https://doi.org/10.1016/j.nedt.2003.10.001
[25]
Palinkas, L.A., Horwitz, S.M., Green, C.A., Wisdom, J.P., Duan, N. and Hoagwood, K. (2015) Purposeful Sampling for Qualitative Data Collection and Analysis in Mixed Method Implementation Research. AdministrationandPolicyinMentalHealthandMentalHealthServicesResearch, 42, 533-544. https://doi.org/10.1007/s10488-013-0528-y
[26]
Abadie, R., Welch-Lazoritz, M., Khan, B. and Dombrowski, K. (2017) Social Determinants of HIV/HCV Co-Infection: A Case Study from People Who Inject Drugs in Rural Puerto Rico. AddictiveBehaviorsReports, 5, 29-32. https://doi.org/10.1016/j.abrep.2017.01.004
[27]
Jovet-Toledo, G.G., Clatts, M.C., Rodriguez-Diaz, C.E., Goldsamt, L. and Vargas-Molina, R.L. (2014) Risk Factors for Suicide Attempts in a Clinic-Based Sample of People Living with HIV in Puerto Rico. AIDSCare, 26, 1032-1035. https://doi.org/10.1080/09540121.2014.894618
[28]
Reader, S.W., Kim, H., El-Serag, H.B. and Thrift, A.P. (2020) Persistent Challenges in the Hepatitis C Virus Care Continuum for Patients in a Central Texas Public Health System. OpenForumInfectiousDiseases, 7, ofaa322. https://doi.org/10.1093/ofid/ofaa322
[29]
Terrault, N.A. (2019) Hepatitis C Elimination: Challenges with Under-Diagnosis and Under-Treatment. F1000Research, 8, Article 54. https://doi.org/10.12688/f1000research.15892.1
[30]
Ortiz-Sánchez, E.J., Rodríguez-Díaz, C.E., Jovet-Toledo, G.G., Santiago-Rodríguez, E.I., Vargas-Molina, R.L. and Rhodes, S.D. (2016) Sexual Health Knowledge and Stigma in a Community Sample of HIV-Positive Gay, Bisexual, and Other Men Who Have Sex with Men in Puerto Rico. JournalofHIV/AIDS&SocialServices, 16, 143-153. https://doi.org/10.1080/15381501.2016.1169467
[31]
Epstein, S. (1995) The Construction of Lay Expertise: AIDS Activism and the Forging of Credibility in the Reform of Clinical Trials. Science, Technology, &HumanValues, 20, 408-437. https://doi.org/10.1177/016224399502000402
